Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas

Immunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. Immune checkpoint inhibitors (CPIs) targeting the PD-1 and CTLA-4 axes have demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerrison, William G. J., Lee, Alexander T. J., Thway, Khin, Jones, Robin L., Huang, Paul H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945421/
https://www.ncbi.nlm.nih.gov/pubmed/35327375
http://dx.doi.org/10.3390/biomedicines10030573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945421/
https://www.ncbi.nlm.nih.gov/pubmed/35327375
http://dx.doi.org/10.3390/biomedicines10030573

Ejemplares similares